Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (March 2023)
32 slides from Imagion Biosystems's investor presentation, Mar 7, 2023
Slide 1: Investor Presentation
Changing the way we look at cancer Investor Presentation 7 March 2023 Imagion Biosystems Limited ImagionBiosystems.com ASX:IBX
Slide 2: Disclaimers
Disclaimers Imagionbiosystems.com This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwri
Slide 3: Imagion Biosystems Overview
Imagion Biosystems Overview Imagionbiosystems.com We are a clinical stage medical imaging company Imagion Biosystems developing next generation molecular imaging ASX:IBX technologies Market cap: ~$25 million Innovative medical imaging using bio-safe magnetic nanoparticles Cash at 31 Dec 2022: $4.4 m
Slide 4: Investment Highlights
Investment Highlights Imagionbiosystems.com $ Product Pipeline Addresses MagSense® Technology 4 Key Initial Clinical Large Markets & Unmet Will Transform Cancer Multiple Revenue Strong Leadership and Milestones Achieved Needs Diagnosis Opportunities Advisory Boards First product for HER2 First 3 pro
Slide 5: A Global Medical Need
01 A Global Medical Need $100 billion spent annually to diagnose or detect Each year cancer kills 9 million people globally cancer, yet cancer continues to be a leading cause of mortality and morbidity. 5
Slide 6: A Growing Global Health Problem
A Growing Global Health Problem Imagionbiosystems.com 1 in 3 people are affected by cancer US$100 BILLION CANCER DIAGNOSTICS MARKET $30,000 $26.0b $25,000 $20.1b $20,000 Millions (USD) $15.5b $15,000 $9.6b $10,000 $8.9b $7.2b $5.9b $3.1b $4.6b $5,000 $- Blood Pancreatic Kidney Ovarian Liver Prostate
Slide 7: Clear Unmet Medical Need
Clear Unmet Medical Need Imagionbiosystems.com Anatomical images can’t differentiate benign from malignant lesions 7
Slide 8: MagSense Technology
02 MagSense® Technology 8
Slide 9: Enabling Molecular Imaging
Enabling Molecular Imaging Imagionbiosystems.com MagSense® Technology aims to transform how medical imaging can detect and diagnose cancer Non-invasive – a safe and non-surgical solution to detect cancer Conventional methods are not specific and can only identify a region of interest No radioactivit
Slide 10: How It Works
How It Works Imagionbiosystems.com Bio-safe magnetic nanoparticles are attracted to the tumor and detected Patients are given a low dose injection of the nanoparticle imaging agent Targeting molecules affixed to the nanoparticles, ensure high specificity for the cancer, and cause the nanoparticles t
Slide 11: MagSense Molecular Imaging
MagSense® Molecular Imaging Imagionbiosystems.com 1 2 3 4 Clinical assessment MagSense® nanoparticle MRI detects change in Physician sees molecular identifies need for test imaging agent given to image contrast from image signature if tumor patient imaging agent present Works within current cancer d
Slide 12: How It Works - Video
How It Works - Video Imagionbiosystems.com Click play to watch video in browser 12
Slide 13: Broad Commercial Applicability
Broad Commercial Applicability Imagionbiosystems.com MagSense® imaging agents can be 1 Brain Cancer developed for many types of solid tumors 2 Lung Cancer and can be used at multiple stages of 3 Breast Cancer diagnosis including primary diagnosis, staging, and monitoring the effectiveness 4 Ovarian
Slide 14: The Phase I Clinical Study
The Phase I Clinical Study Imagionbiosystems.com Detection of Nodal Metastases in HER2+ Breast Cancer No issues of safety or tolerability related to the imaging agent reported to date Data reported show the imaging agent results in a detectable magnetic signature by both imaging methods - MRI and MR
Slide 15: MagSense Imaging with MRI
MagSense Imaging with MRI ® Imagionbiosystems.com Changing the way we look at cancer Pre-Dose T2 Data from the Phase I study indicates our molecularly targeted nanoparticles could be effective in detecting nodal disease when used in conjunction with conventional MRI scanners Improves radiological re
Slide 16: Growth Strategy
03 Growth Strategy 16
Slide 17: Leveraging MRI
Leveraging MRI Imagionbiosystems.com Accelerating our path to commercial product The Market Path to Commercialisation R&D Benefits Increases addressable market by Path to market simpler, Pipeline of targeted imaging now targeting the large installed eliminating the challenges and agents for addition
Slide 18: Business Strategy
Business Strategy Use MagSense® HER2 Expand the pipeline Collaborate in other Create a high-value Test as a commercial biomedical applications biomedical portfolio launchpad Build a pipeline of diagnostic imaging agents Generate revenue through Align with strategic partners Current Phase 1 study tar
Slide 19: MagSense Product Pipeline
MagSense® Product Pipeline Imagionbiosystems.com Applying targeted imaging to other cancers Note: The pipeline above provides no guidance as to timing and is indicative and subject to change 19
Slide 20: Compelling Business Model
Compelling Business Model Imagionbiosystems.com Proprietary Consumables Drive Growth & Profitability Injectable Each Cancer Test Billable MagSense® ~$1,500 USD* Imaging Agents ~80% Gross Margin* Direct Sales Partnerships Licensing Tests can be sold to Enables strategic Licensing/milestone any hospit
Slide 21: Funding
04 Funding 21
Slide 22: Funding Update
Funding Update Imagionbiosystems.com Entitlement offer and funding package Non-renounceable entitlement offer raise up to A$2.4m (“Entitlement Offer”) Funding package with Mercer Street Global Opportunity Fund, LLC (Mercer) of up to A$15m • Initial investment of A$1.5m via convertible securities • F
Slide 23: Entitlement Offer
Entitlement Offer Imagionbiosystems.com Details of the Entitlement Offer Offer Timetable Offer Structure Event Date • Non-renounceable pro-rata entitlement offer raise approximately A$2.4m on the basis for 1 share for every 8 shares held • Entitlement Offer is not underwritten and no minimum subscri
Slide 24: Mercer Transaction
Mercer Transaction Imagionbiosystems.com Growth funding package Funding package with Mercer Street Global Opportunity Fund, LLC (Mercer) of up to $15m • Initial investment of $1.5m via convertible securities • Further investment of $1.0m via convertible securities subject to shareholder approval at
Slide 25: Mercer Transaction
Mercer Transaction Imagionbiosystems.com Key terms of the agreement: Term Ownership limitation • 18-month term for each tranche from drawdown • At no point in time will Mercer own more than 9.99% of the shares of Imagion Conversion • 90% lowest VWAP during 15 trading days (all tranches) or Option co
Slide 26: Leadership and Financials
05 Leadership and Financials 26
Slide 27: Experienced Board and Management
Experienced Board and Management Imagionbiosystems.com Commercially focused team with deep industry & clinical experience ROBERT PROULX YALIA JAYALAKSHMI MICHAEL HARSH DAVID LUDVIGSON DIANNE ANGUS CHAIRMAN & CEO CHIEF DEVELOPMENT OFFICER NON-EXEC DIRECTOR NON-EXEC DIRECTOR NON-EXEC DIRECTOR • Operat
Slide 28: Scientific Advisory Board
Scientific Advisory Board Imagionbiosystems.com Collective expertise in oncology, medical imaging, nanotechnology, clinical trial design DR JOHN HAZLE PROF LISA HORVARTH DR ROBERT IVKOV SCIENTIFIC ADVISORY BOARD CHAIR • Director, Department of Medical Oncology, • Expertise in radiation oncology and
Slide 29: Collaborators and Partners
Collaborators and Partners Imagionbiosystems.com MD Anderson Cancer Center - In 2015 the MD Anderson established a Magnetic Relaxometry Research Laboratory to help validate the Imagion technology for various cancer targets World class scientific collaborations & partnerships: UC San Diego - Radiolog
Slide 30: Capital and Financial Snapshot
Capital and Financial Snapshot Imagionbiosystems.com Ordinary shares on issue 1,121 million Imagion ended Q4 2022 with $4.4 million Listed and unlisted options 290 million Share price (6 March 2023) $0.022 R&D tax incentive of $2.5 million 12-month range $0.02 - $0.063 received in Q42022 Average dai
Slide 31: Historical Cash Flows
Historical Cash Flows Imagionbiosystems.com 2020 2021 2022 Q1 AUD Q2 AUD Q3 AUD Q4 AUD Q1 AUD Q2 AUD Q3 AUD Q4 AUD Q1 AUD Q2 AUD Q3 AUD Q4 AUD Operating '000 '000 '000 '000 '000 '000 '000 '000 ’000 ’000 ‘000 ‘000 Receipts from customers 50 26 82 65 41 48 34 84 95 143 88 88 Payments - R&D (492) (1,03
Slide 32: www.imagionbiosystems.com info@imagionbio.com ASX:IBX
www.imagionbiosystems.com info@imagionbio.com ASX:IBX
Imagion Biosystems — Investor Presentation (March 2023) on 6ix